Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Working closely with the University of British Columbia (UBC)'s Support Program to Advance Research Capacity (SPARC), MORU Malaria Researcher Dr Katherine Plewes was recently awarded a 3-year, C$971,551 grant for her study on Evaluating the renoprotective effect of acetaminophen in pediatric severe falciparum malaria: A randomized controlled trial.

Katherine Plewes

The study, a much larger version of Katherine’s earlier randomized controlled trial in adults with severe malaria in Chittagong, Bangladesh that showed that paracetamol improved kidney function and reduced the odds of developing Acute kidney injury (AKI), an important problem that contributes to an estimated 1.7 million deaths annually.

As children bear the major burden of malaria, Katherine’s study will test this protective effect in on African children, where AKI affects up to 45% of patients. With an ultimate goal to assess the role of paracetamol as a renoprotective adjunctive therapy in severe malaria, Katherine with Dr Caterina Fanello and the team at DR Congo will conduct at KIMORU, Kinshasa a randomized controlled trial of adjunctive paracetamol in 460 African children with severe malaria. The study  is expected to begin in September 2019.

Arjen Dondorp (MORU) is co-primary grant applicant. Dr. Caterina Fanello, Dr. Marie Onyamboko (both KIMORU), Prof Kevin Kain (University of Toronto), Dr. Adeera Levin (UBC) and Dr. Mavuto Mukaka (MORU) are co-applicants, and Prof John Oates (Vanderbilt University) is collaborator.

Similar stories

Congratulations to Professor Sir David Warrell, appointed Knight Commander of the Order of St Michael and St George!

David Warrell, MORU founding director, has been appointed by the Queen ‘Knight Commander of the Order of St Michael and St George for services to global Health Research and Clinical Practice’. Please join us in congratulating Sir David on receiving this richly deserved high honour!

Laos’ first Pint of Science: warty newts, COVID, AI for Instagram, and more!

Organised by a grass-root community of thousands of scientists across the world, Pint of Science 2022 allows researchers in 25 countries and over 800 cities to share their latest findings with lay folk in interesting, informal settings. Lao PDR joined the global Pint of Science family on Monday 9 May, when the first-ever Pint of Science Laos kicked off!

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

PRIORITISE study team publishes results, now seeks partners

In regions where few people have received Covid-19 vaccines, health systems remain vulnerable to surges in SARS-CoV-2 infections. During the delta-wave of COVID-19 in India, for example, healthcare facilities and staff across the country struggled to cope with the surge in the number of cases of COVID-19 due to a shortage of hospital beds for people with severe cases, plus shortages of medicines and limited human resources.

Under the Mask, drama film based on testimonies of tuberculosis patients

In 2022, tuberculosis (TB) remains a major global health problem, particularly in developing countries. On the Thai-Myanmar border, TB is an important problem among migrants, a vulnerable, very mobile population, with unstable, often difficult living conditions, insecure incomes, and poor access to health services.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.